Basis for effective combination cancer chemotherapy with antimetabolites

Pharmacology and Therapeutics

Volumn 87, Issue 2-3, 2000, Pages 227-253

  Peters, G J ^a   Van Der Wilt, C L ^a   Van Moorsel, C J A ^a   Kroep, J R ^a   Bergman, A M ^a   Ackland, S P ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

5 Fluorouracil; Antimetabolites; Deoxycytidine kinase; Gemcitabine; Median drug effect analysis; Thymidylate synthase

Indexed keywords

ALLOPURINOL; AMSACRINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; CISPLATIN; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DIHYDROFOLATE REDUCTASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INTERFERON; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; PREDNISONE; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; UNINDEXED DRUG; URIDINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HUMAN; LUNG CANCER; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG THERAPY; FLUOROURACIL; HUMAN; LEUCOVORIN; LEUKEMIA; NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 0033801694     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00086-3     Document Type: Conference Paper

References (229)

1. Abratt R.P., Bezwoda W.R., Goedhals L., Hacking D.J. Weekly gemcitabine (days 1, 8, 15) with monthly cisplatin (day 15). active combination chemotherapy for advanced non-small cell lung cancer J Clin Oncol. 15:1997;744-749.
2. Abratt R.P., Sandler A., Crinò L., Steward W.P., Shepherd F.A., Green M.R., Nguyen B., Peters G.J. Combined cisplatin and gemcitabine for non-small cell lung cancer. influence of scheduling on toxicity and drug delivery Semin Oncol. 25(suppl. 9):1998;35-43.
3. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol. 12:1994;960-969.
4. Aleman B.M.P., Bartelink H., Gunderson L.L. The current role of radiotherapy in colorectal cancer. Eur J Cancer. 31A:1995;1333-1339.
5. Arbuck S.G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 63:1989;1036-1044.
6. Ardalan B., Singh G., Silberman H. A randomized Phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic colorectal cancers. J Clin Oncol. 6:1988;1053-1058.
7. Baccanari D.P., Davis S.T., Knick V.C., Spector T. 5-Ethynyluracil. effects on the pharmacokinetics and antitumor activity of 5-fluorouracil Proc Natl Acad Sci USA. 90:1993;11064-11068.
8. Bagrij T., Kralovanszky J., Gyergyay F., Kiss E., Peters G.J. Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil. Anticancer Res. 13:1993;789-794.
9. Balzarini, J. (2000). Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reserve transcriptase inhibitors. Pharmacol Ther, this volume.
10. Bauknecht T., Grieshaber C.H., Breitbach G.-P. Gemcitabine (gem) in combination with cisplatin (SP) in previously untreated patients ≥60 years with FIGO stage IIIC or IV epithelial ovarian cancer. a phase II study: preliminary results Proc Am Soc Clin Oncol. 17:1998;365a.
11. Bazin I., Garin A., Bulat J., Zharkov S., Popov A. Preliminary results of gemzar + mitomycin in treatment of advanced pancreatic cancer. Ann Oncol. 9(suppl. 2):1998;178.
12. Berenbaum M.C. What is synergy? Pharmacol Rev. 41:1989;93-141.
13. Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Peters G.J. Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res. 2:1996;521-530.
14. Bergman A.M., Pinedo H.M., Jongsma A.P.M., Brouwer M., Ruiz van Haperen V.W.T., Veerman G., Leyva A., Eriksson S., Peters G.J. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycytidine) of cytosine-arabinoside resistant myeloblastic murine and rat leukemia cell lines. role of altered activity and substrate specificity of deoxycytidine kinase Biochem Pharmacol. 57:1999;397-406.
15. Bhalla K., Cole J., MacLaughlin W., Arlin Z., Baker M., Graham G., Grant S. Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2′-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells. Leukemia. 1:1987;814-819.
16. Bhalla K., Birkhofer M., Grant S., Baker M., MacLaughlin W., Cole J., Graham G. Phase I clinical and pharmacologic study of deoxycytidine. Leukemia. 2:1988;709-710.
17. Bleiberg H., De Gramont A. Oxaliplatin plus 5-fluorouracil. clinical experience in patients with advanced colorectal cancer Semin Oncol. 25(suppl. 5):1998;32-39.
18. Bökkerink J.P., Bakker M.A., Hulscher T.W., De Abreu R.R., Schretlen E.D., Van Laarhoven J.P., Bruyn C.H. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol. 35:1986;3549-3555.
19. Bouffard D.Y., Momparler R.L. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res. 19:1995;849-856.
20. Braakhuis B.J.M., Ruiz van Haperen V.W.T., Boven E., Veerman G., Peters G.J. Schedule dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol. 22(suppl. 11):1995;42-46.
21. Buyse M. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 88:1996;252-258.
22. Byrne M.J., Davidson J.A., Muske A.W., Dewar J., van Hazel G., Buck M., de Klerk N., Robinson B.W.S. Cisplatin (C) and gemcitabine (G) treatment for malignant mesothelioma. a phase II study Proc Am Soc Clin Oncol. 17:1998;464a.
23. Camitta B., Leventhal B., Lauer S., Shuster J.J., Aclair S., Casper J., Civin C., Graham M., Mahoney D., Munoz L. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood. a Pediatric Oncology Group study J Clin Oncol. 7:1989;1539-1544.
24. Cao S., Rustum Y.M., Spector T. 5-Ethynyluracil (77C85). modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma Cancer Res. 54:1994;1507-1510.
25. Cao S., Frank C., Shirasaka T., Rustum Y.M. 5-Fluorouracil prodrug. role of anabolic and catabolic pathway modulation in therapy of colorectal cancer Clin Cancer Res. 1:1995;839-845.
26. Caponigro F., Casaretti R., McLeod H.L., Budillon A., De Vita F., Avallone A., Cartine G., Gravina A., Barbarulo D., Morsman J., Fiore F., Catalano G., Comella P., Comella G. Phase I and pharmacokinetic study of Tomudex (TOM) + 5-fluorouracil (5-FU)/levofolinic acid (LFA) in advanced head and neck and colorectal cancer. Proc Am Assoc Clin Oncol. 17:1998;237a.
27. Cardenal F., Lopez-Carerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., Barneto I., Lomas M., Garcia M., Lianes P., Montalar J., Vadell C., Gonzalez-Larriba J.L., Artal A., Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 17:1999;12-18.
28. Cascinu, S., Silva, R. R., Barni, R., Labianca, R., Frontini, L., Pancera, G., Zaniboni, A., Ferretti, B., Giordani, P., Pessi, M. A., Fusco, V., Luporini, G., Catalano, G., & Cellerino, R., on behalf of GISCAD (Italian Group for the Study of Digestive Tract Cancer) (1998). Gemcitabine (gem) and 5-fluorouracil (5FU) in advanced pancreatic cancer: a giscad phase II study. Proc Am Soc Clin Oncol 17, 264a.
29. Castellano D., Lianes P., Calzas J., García-Carbonero R., Guerra J.A., Gómez H., Cortés-Funes H. Non-cisplatin-based chemotherapy for advanced non small-cell lung cancer (NSCLC). a phase II study with gemcitabine (G), ifosfamide (I) and vinorelbine (N) Proc Am Soc Clin Oncol. 17:1998;480a.
30. Chessells J.M. Acute leukaemia in childhood. Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. 1995;1628-1647 Oxford University Press, Oxford.
31. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships. the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Reg. 11:1984;27-55.
32. Christer J.F.M., Sederholm M.D. A pilot study of gemcitabine plus carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 18:1999;490a.
33. Chu E., Koeller D., Casey J., Drake J., Chabner B., Elwood P., Zinn S., Allegra C. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA. 88:1991;8977-8981.
34. Chu E., Koeller D.M., Johnston P.G., Zinn S., Allegra C.J. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol. 43:1993;527-533.
35. Codacci-Pisanelli G., Van der Wilt C.L., Pinedo H.M., Francchi F., Noordhuis P., Van Laar J.A.M., Braakhuis B.J.M., Peters G.J. Antitumor activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Eur J Cancer. 31A:1995;1517-1525.
36. Codacci-Pisanelli G., Kralovansky J., Van der Wilt C.L., Noordhuis P., Colofiore J.R., Martin D.S., Franchi F., Peters G.J. Modulation of 5-fluorouracil in mice using uridine diphosphoglucose. Clin Cancer Res. 3:1997;309-315.
37. Cohen J.D., Strock D.J., Teik J.E., Katz T.B., Marcel P.D. Deoxycytidine in human plasma. potential for protecting leukemic cells during chemotherapy Cancer Lett. 116:1997;167-175.
38. Colucci G., Giuliani F., Riccardi F., Lopez M., Gebbia V., Pedicini A., Biglietto M., Cartenì G., Maiello E., Gebbia N. Gemcitabine alone or with cisplatin in advanced pancreatic cancer. preliminary results of a randomized study of the southern Italy oncology group Proc Am Soc Clin Oncol. 17:1998;289a.
39. Conti J.A., Kemeny N., Seiter K., Goker E., Tong W., Andre M., Ragusa K., Bertino J.R. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol. 12:1994;695-700.
40. Corbett T.H., Roberts B.J., Trader M.W., Laster W.R. Jr., Grisword D.P. Jr., Schaber F.M. Jr. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep. 66:1982;1187-1200.
41. Crinó L., Scagliotti G., Marangolo M. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC). A phase II study. J Clin Oncol. 15:1997;297-303.
42. Crinó L., Conte P., De Marinis F., Rinaldi M., Gridelli C., Ceribelli A., Matano E., Marangolo M., Bartolucci R., Oliva C., Tonato M. A randomised trial of gemcitabine cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). A multicenter phase III study. Proc Am Soc Clin Oncol. 17:1998;455a.
43. Cronauer M.V., Klocker H., Talasz H., Geisen F.H., Hobisch A., Radmayr C., Bock G., Culig Z., Schirmer M., Reissigl A., Bartsch G., Konwalinka G. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate. 28:1996;172-181.
44. Csapó Zs., Keszler G., Sasvári-Székely M., Smid K., Noordhuis P., Peters G.J., Staub M. Similar changes were induced by cladribine and by gemcitabine, in the deoxypyrimidine salvage, during short term treatments. Adv Exp Med Biol. 431:1998;525-529.
45. Cvitkovic E. Ongoing and unsaid on oxaliplatin. the hope Br J Cancer. 77(suppl. 4):1998;8-11.
46. De Gusmão C.B.R.A., Murad A.M., Scalabrini-Neto A.O. Phase II trial of the use of gemcitabine (g) and 5-fluorouracil (5-FU) in the treatment of advanced pancreatic (APC) and billary tract (ABTC) adenocarcinoma. Proc Am Soc Clin Oncol. 17:1998;290a.
47. Elion G.B. Selectivity - key to chemotherapy. presidential address Cancer Res. 45:1985;2943-2950.
48. Elion G.B., Singer S., Hitchings G.H. Antagonists of nucleic acid derivatives. Part VIII. Synergism in combinations of biochemically related antimetabolites J Biol Chem. 208:1954;477-488.
49. Eriksson S., Wang L.Y. Substrate specificities, expression and primary sequences of deoxynucleoside kinases - implications for chemotherapy. Nucleosides & Nucleotides. 16:1997;653-659.
50. Esteban E., Llano J.L.G., Vieitez J.M., Fra J., Puertas J., Estrada E., Palacio I., Muñiz I., Buesa J.M., Lacave A.J. Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 17:1998;482a.
51. Fielding J.W.L., Hallissey M.T., Timothy A.R., Wrigley P.F.M. Cancer of the stomach. Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. 1995;1095-1116 Oxford University Press, Oxford.
52. Fischel J.L., Etienne M.C., Formento P., Milano G. Search for the optimal schedule for the oxaliplatin/5fluorouracil association modulated or not by folinic acid - preclinical data. Clin Cancer Res. 4:1998;2529-2535.
53. Frei E. III, Elias A., Wheeler C., Richardson P., Hryniuk W. The relationship between high-dose treatment and combination chemotherapy. the concept of summation dose intensity Clin Cancer Res. 4:1998;2027-2037.
54. Fujii S., Ikenada K., Fukushima M., Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann. 69:1978;763-772.
55. Fujita, H., Okamoto, M., Takao, A., Matsushima, E., & Shirasaka, T. (1993). Preclinical studies of S-1, a new oral tegafur, plus modulators: pharmacokinetics. Rec Adv Chemother, 928-929.
56. Gandhi V., Kemena A., Keating M.J., Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 52:1992;897-903.
57. Gandhi V., Estey E., Keating M.J., Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 11:1993;116-124.
58. García-Carbonero R., Hitt R., Castellano D., Calzas J., Hidalgo M., Brandariz A., Peña M., Cortés-Funes H. Phase II trial of cisplatin (C) and gemcitabine (G) in advanced squamous cell carcinoma of the head and neck (AHNC). Proc Am Soc Clin Oncol. 17:1998;392a.
59. García Conde J., Lluch A., Pérez-Manga G., Palomero I., Alba E., Rueda A., Moreno Noguiera J.A., Calvo E., Tarazona Y., López-Martín E. Gemcitabine and doxorubicin in advanced breast cancer. final results from an early phase II study Proc Am Soc Clin Oncol. 16:1997;147a.
60. Gatzemeier U., Manegold C., Eberhard W., Wilke H.J., Chomy F., Chomy P., Khayat D., Blatter J., Seeber S., Drings P. A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. Semin Oncol. 24(suppl. 8):1997;36-38.
61. Gennari A., Donati S., Danesi R., Fogli S., Orlandini C., Del Tacca M., Conte P.F. The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. Semin Oncol. 27(1 suppl. 2):2000;14-19.
62. Georgoulias V., Kourousis C., Androulakis N., Kakolyris S., Dimopoulos M.A., Bouros D., Papadimitriou C., Hatzakis K., Heras P., Kalbakis K., Kotsakis T., Vardakis N., Meramveliotakis N., Hatzidaki D. Docetaxel (taxotere) and gemcitabine in the treatment of non-small cell lung cancer. preliminary results Semin Oncol. 24(suppl. 14):1997;22-25. a.
63. Georgoulias V., Kourousis C., Kakolyris S., Androulakis N., Dimopoulos M.A., Papadakis E., Kotsakis T., Vardakis N., Kalbakis K., Merambeliotakis N., Hatzidaki D. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine. a preliminary report on an active regimen Semin Oncol. 24(suppl. 12):1997;61-66. b.
64. Georgoulias V., Kouroussis Ch., Androulakis N., Kakolyris S., Dimopoulos A.M., Papadakis E., Papadimitriou Ch., Hatzakis K., Bania E., Apostolopoulou F., Tsiafaki X., Alexopoulos A., Souglakos J., Kotsakis Th., Vlachonicolis J., Hatzidaki D. Front-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel (D) and gemcitabine (G). a multicenter phase II trial Proc Am Soc Clin Oncol. 17:1998;473a.
65. Giaccone G. New drugs in non-small cell lung cancer. an overview Lung Cancer. 12:1995;S155-S162.
66. Giaccone G., Smit E.F., van Meerbeeck J.P., Splinter T., Golding R.P., Pinedo H.M., Laan D., van Tinteren H., Postmus P. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol. 11:2000;109-112.
67. Giverhaug T., Loennechen T., Aarbakke J. Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate. Biochem Pharmacol. 55:1998;1641-1646.
68. Gralla R.J., Rittenberg C.N., Silverman C.R., Marques C.B., Maulick J.F., Cole J.T. Gemcitabine (G) + vinorelbine (V) in combination with mitomycin (M) in non-small cell lung cancer (NSCLC). results of a phase I and phase II study of an active outpatient regimen Proc Am Soc Clin Oncol. 17:1998;486a.
69. Grant S. Biochemical modulation of cytosine arabinoside. Pharmacol Ther. 48:1990;29-44.
70. Grant S. Ara-C. cellular and molecular pharmacology Adv Cancer Res. 72:1998;197-233.
71. Grant S., Baker M., Bhalla K. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2′-deoxycytidine (IND 28108) in patients with refractory leukemia. an interim report Leukemia. 7:1993;1933-1938.
72. Greco W.R., Bravo G., Parsons J.C. The search for synergy. a critical review from a response surface perspective Pharmacol Rev. 47:1995;331-385.
73. Grem J.L., Fischer P.H. Enhancement of 5-fluorouracil anticancer activity by dipyridamole. Pharmacotherapy. 40:1989;349-371.
74. Grem J.L., Hoth O.F., Hamilton J.M., King S.A., Leyland-Jones B. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep. 71:1987;1249-1264.
75. Grem J.L., King S.A., O'Dwyer P.J., Leyland-Jones B. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate. a review Cancer Res. 48:1988;4441-4454.
76. Grem J.L., Jordan E., Robson M.E., Binder R.A., Hamilton J.M., Steinberg S.M., Arbuck S.G., Beveridge R.A., Kales A.N., Miller J.A., Weiss R.B., Mcatee N., Chen A., Goldspiel B., Sover E., Allegra C.J. Phase-II study of fluorouracil, leucovorin, and interferon α-2a in metastatic colorectal carcinoma. J Clin Oncol. 11:1993;1737-1745.
77. Gruber J., Geisen F., Sgonc R., Egle A., Villunger A., Boeck G., Konwalinka G., Greil R. 2′,2′-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA). Stem Cells. 14:1996;351-362.
78. Guichard S., Cassac D., Hennebelle I., Bugat R., Canal P. Sequence dependent activity of the irinotecan-5FU combination in human colon cancer model HT-29 in vitro and in vivo. Int J Cancer. 73:1997;729-734.
79. Guichard S., Hennebelle I., Bugat R., Canal P. Cellular interactions of 5-fluorouracil and the campthothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol. 55:1998;667-676.
80. Hainsworth J.D., Erland J.B., Kalman L.A., Hon J.K., Smith S.W., Greco F.A. Phase I/II trial of paclitaxel (1-hour infusion), carboplatin, and gemcitabine in the treatment of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 17:1998;471a.
81. Haller D.G. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer. 31A:1995;1255-1263.
82. Harstrick A., Mayer S., Muller C., Hilger R., Dohmen D., Kreisel C., Vanhoefer U., Scheulen M.E., Wilke H., Seeber S. Combination therapy with infusional 5-FU and "tomudex" for patients (PTS) with advanced colorectal cancer - a phase I study. Proc Am Assoc Clin Oncol. 17:1998;200a.
83. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
84. Heinemann V., Xu Y.-Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 38:1990;567-572.
85. Heinemann V., Xu Y.-Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate, a mechanism of self-potentiation. Cancer Res. 52:1992;533-539.
86. Heinemann V., Schulz L., Issels R.D., Plunkett W. Gemcitabine - a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 22(suppl. 11):1995;11-18.
87. Hidalgo M., Castellano D., Paz-Ares L., Gravalos C., Diaz-Puente M., Hitt R., Alonso S., Cortes-Funes H. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol. 17:1999;585-592.
88. Hines J.D., Adelstein D.J., Spiess J.L., Giroski P., Carter S.G. Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. plasma and tissue pharmacokinetics Cancer. 63:1989;1022-1025.
89. Hoelzer D. Acute leukaemias in adults. Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. 1995;1608-1628 Oxford University Press, Oxford.
90. Houghton J.A., Houghton P.J., Wooten R.S. Mechanism of induction of the gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res. 39:1979;2406-2413.
91. Houghton J.A., Morton C.L., Adkins D.A., Rahman A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha-2A in colon carcinoma cells. Cancer Res. 53:1993;4243-4250.
92. Houghton J.A., Cheshire P.J., Hallman J.D.N., Lutz L., Luo X., Li Y., Houghton P.J. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon carcinoma cell lines. Clin Cancer Res. 2:1996;107-118.
93. Hryniuk W.M., Figueredo A., Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol. 14(suppl. 14):1987;3-11.
94. Huang P., Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem. 207:1992;163-167.
95. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′,2′-difluorodeoxycitidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
96. Hudis C.A. Cyclophosphamide, methotrexate, and fluorouracil. still the gold standard? J Clin Oncol. 14:1996;1971-1973.
97. Ikenaka K., Shirasaka T., Kitano S., Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann. 70:1979;353-359.
98. Isokangas O.P., Mattson K., Joensuu H., Tamminen K., Nikkanen V., Viren M., Brisgand D., Barbet I. A phase II study of vinorelbine (VNR) and gemcitabine (GEM) in inoperable stage IIIB-IV NSCLC. Proc Am Soc Clin Oncol. 17:1998;489a.
99. Jackman A.L., Boyle F.T., Harrap K.R. Tomudex™ (ZD1694) - from concept to care, a programme in rational drug discovery. Invest New Drugs. 14:1996;305-316.
100. Jackson R.C., Fry D.W., Boritzki T.J., Besserer J.A., Leopold W.R., Sloan B.J., Elslager E.F. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul. 22:1984;187-206.
101. Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates. Jackman A.L. Antifolate Drugs in Cancer Therapy. 1999;293-321 Humana Press Inc, Totowa.
102. Kanzawa F., Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol. 24(suppl. 7):1997;8-16.
103. Kaufman D., Stadler W., Carducci M., Raghavan D., Murphy B., Aisner J., Kuzel T., John W., Voi M. Gemcitabine (gem) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC). final results of a phase II study Proc Am Soc Clin Oncol. 17:1998;320a.
104. Kelsen D.P., Martin D., O'Neil J., Schwartz G., Saltz L., Sung M.T., Von Borstel R., Bertino J. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol. 15:1997;1511-1517.
105. Kemeny N. Review of regional therapy of liver metastases in colorectal cancer. Semin Oncol. 19(suppl. 3):1992;155-162.
106. Klubes P., Leyland-Jones B. Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue. Pharmacol Ther. 41:1989;289-302.
107. Köhne C.H., Schöffski P., Wilke H., Kaufer C., Andreesen R., Ohl U., Klaasen U., Westerhausen M., Hiddemann W., Schott G., Harstrick A., Bade J., Horster A., Schubert U., Hecker H., Dorken B., Schmoll H.J. Effective biomodulation by leucovorin of high dose infusional fluorouracil given as a weekly 24-hour infusion. results of a randomized trial in patients with advanced colorectal cancer J Clin Oncol. 16:1998;418-426.
108. Köhne-Wömpner C.H., Schmoll H.J., Harstrick A., Rustum Y.M. Chemotherapeutic strategies in metastatic colorectal cancer - an overview of current clinical trials. Semin Oncol. 19:1992;105-125.
109. Kornek G.V., Haider K., Bareck E., Raderer M., Valencak V., Kwansny W., Depisch D., Kovats E., Puribauer F., Lang F.C., Hejna M., Scheithauer W. Treatment of advanced breast cancer with gemcitabine & vinorelbine (VLB), and human granulocyte colony stimulating factor (GCSF). Ann Oncol. 9(suppl. 2):1998;169.
110. Kosmidis P.A., Tsavaris N., Skarlos D., Theocharis D., Samantas E., Pavlidis N., Briassoulis E., Fountzilas G. Fluorouracil and leucovorin with or without interferon α-2b in advanced colorectal cancer. analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group J Clin Oncol. 14:1996;2682-2687.
111. Krakowski I., Petit T., Kayitalire L., Weber B., Beaudouin M., Canon J.L., Janssens J., Martin C., Belpomme D. Gemcitabine (Gemzar®) in combination with cisplatin (CP) in advanced ovarian cancer (AOC). a phase II study Proc Am Soc Clin Oncol. 17:1998;356a.
112. Kroep J.R., Giaccone G., Voorn D.A., Smit E., Beijnen J.H., Rosing H., Van Moorsel C.J.A., Van Groeningen C.J., Postmus P.E., Pinedo H.M., Peters G.J. Gemcitabine and paclitaxel; pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J Clin Oncol. 17:1999;2190-2197.
113. Kunkel L.M., Evans S.S., Dottino P.R., DiSaia P.J., Nagourney R.A. Cisplatin (CDDP) & gemcitabine (dFdC) in relapsed ovarian cancer. Proc Am Soc Clin Oncol. 17:1998;357a.
114. Lamont E.B., Schilsky R.L. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 5:1999;2289-2296.
115. Lawrence T.S., Chang E.Y., Hahn T.M., Hertel L.W., Shewach D.S. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872.
116. Leichman C.G., Fleming T.R., Muggia F.M., Tangen C.M., Ardalan B., Doroshow J.H., Meyers F.L., Holcombe R.F., Weiss G.R., Mangalik A. Phase II study of fluorouracil and its modulation in advanced colorectal cancer. a Southwest Oncology Group study J Clin Oncol. 13:1995;1303-1311.
117. Lévi F.A., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Garufi C., Itzhaki M., Dogliotti L. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases. a randomized multi-institutional trial J Natl Cancer Inst. 86:1994;1608-1617.
118. Lévi F., Giacchetti S., Adam R., Zidani R., Metzger G., Misset J.L. Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Eur J Cancer. 31A:1995;1264-1270.
119. Lévi F., Zidani R., Misset J.-L., for the International Organization for Cancer Chronotherapy Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686.
120. Leyland-Jones B., O'Dwyer P. Biochemical modulation. application of laboratory models to the clinic Cancer Treat Rep. 70:1986;219-229.
121. Lilenbaum R.C., Schwartz M.A., Cano R., Krill E., Lutzky J., Blaustein A., Seigel L., Viales M., Dominguez C.J., Davila E. Gemcitabine (gem) and navelbine (nvb) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 17:1998;494a.
122. Loehrer P., Einhorn L.H., Elson P.J., Crawford E.D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M.F., Lowe B.A. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma. a cooperative group study J Clin Oncol. 10:1992;1066-1073.
123. Longo G.S.A., Izzo J., Chang Y.M., Tong W.P., Zielinski Z., Gorlick R., Chou T.-C., Bertino J.R. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin Cancer Res. 4:1998;469-473.
124. Lorusso V., Mancarella S., Carpagnano F., Di Rienzo G., Cisternino L., Napoli G., Orlando S., Cinieri S., Brunetti C., Palazzo S., Catino A., Paradiso A., Panza N., De Cataldis G., Frasci G., De Lena M., for AISCAP Gemcitabine plus vinorelbine in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). A phase II study. Proc Am Soc Clin Oncol. 17:1998;470.
125. Machover D., Grison X., Goldschmidt E., Zittoun J., Lotz J.P., Metzger G., Richaud J., Hannoun L., Marquet J., Guillot T., Salmon R., Sezeur A., Mauban S., Parc R., Izrael V. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma - a phase-I-II study. J Natl Cancer Inst. 84:1992;321-327.
126. Mackey J.R., Baldwin S.A., Young J.D., Cass C.E. Nucleoside transport and its significance for anticancer drug resistance. Drug Resistance Updates. 1:1998;310-324.
127. Mans D.R.A., Grivicich I., Peters G.J., Schwartsmann G. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan - 5-fluorouracil human colon carcinoma cell lines. Eur J Cancer. 35:1999;1851-1861.
128. Martin, D. S. (1987). Biochemical modulation: perspectives and objectives. In K. R. Harrap & T. A. Connors (Eds.), Proceedings of the 8th Bristol-Myers Symposium on Cancer Research. New Avenues in Developmental Cancer Chemotherapy (pp. 113-162). London: Academic Press.
129. Mathe G., Kidani Y., Segiguchi M., Eriguchi M., Fredj G., Peytavin G., Misset J.L., Brienza S., De Vassals F., Chenu E. Oxalato-platinum or L-OHP, a third-generation platinum complex. an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum Biomed Pharmacother. 43:1989;237-250.
130. Mavroudis D., Kouroussis Ch., Malamos N., Potamianou A., Kakolyris S., Alexopoulos A., Androulakis N., Papadakis E., Vlachonikolis J., Kalbakis K., Agelaki S., Kotsakis Th., Sara E., Souglakos J., Samonis G., Georgoulias V., for the Greek Breast Cancer Cooperative Group A phase II trial of docetaxel and gemcitabine as second line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol. 17:1998;158a.
131. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleosides. J Natl Cancer Inst. 88:1996;1193-1203.
132. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 16:1998;301-308. a.
133. Toxicity of fluorouracil in patients with advanced colorectal cancer. effect of administration schedule and prognostic factors J Clin Oncol. 16:1998;3537-3541. b.
134. Mini E., Trave F., Rustum Y.M., Bertino J.R. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther. 47:1990;1-19.
135. Moore M.J., Tannock I., Winquist E., Tolscher A., Bennett K., Seymour L. Gemcitabine (G) + cisplatin (C). an active regimen in advanced transitional cell carcinoma (TCC) Proc Am Soc Clin Oncol. 17:1998;320a.
136. Mullany S., Svingen P.H., Kaufmann S.H., Erlichman C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells - elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol. 42:1998;391-399.
137. Nadal J.C., Van Groeningen C.J., Pinedo H.M., Peters G.J. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma. Invest New Drugs. 7:1989;163-172.
138. Nagourney R.A., Link J., Kunkel L., Evans S. Phase II trial of cisplatin (cddp) & gemcitabine (dfdc) in heavily pretreated breast cancer. Proc Am Soc Clin Oncol. 17:1998;161a.
139. Naguib F.N.M., El Kouni M.H., Cha S. Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver. Biochem Pharmacol. 38:1989;1471-1480.
140. Newling D.W.W., Denis L., Gerard J.P., Scalliet P.G.M., Stoter G. Bladder cancer. Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. 1995;1459-1479 Oxford University Press, Oxford.
141. Nogué M., Cirera L., Arcusa M., Tusquets I., Batieste-Alentorn E., Font A., Boto B. Gemcitabine combined with cisplatin first line. a phase II study in patients with advanced epithelial ovarian cancer Proc Am Soc Clin Oncol. 17:1998;357a.
142. O'Connell M.J. A phase III trial of 5 fluorouracil and leucovorin in the treatment of advanced colorectal cancer. a Mayo Clinic/North Central Cancer Treatment Group study Cancer. 63:1989;1026-1030.
143. O'Dwyer P.J., Paul A.R., Walczak J., Weiner L.M., Litwin S., Comis R.L. Phase II study of biochemical modulation of fluorouracil by low dose PALA in patients with colorectal cancer. J Clin Oncol. 8:1990;1497-1503.
144. O'Reilly S., Rowinsky E.K. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue. 1996 Crit Rev Oncol Hematol. 24:1996;47-70.
145. Padrón J.M., Van Moorsel C.J.A., Bergman A.M., Smitskamp-Wilms E., Van der Wilt C.L., Peters G.J. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. Anticancer Drugs. 10:1999;445-452.
146. Pazdur R. Fluorouracil and recombinant interferon α-2a in advanced gastrointestinal neoplasms. Br J Haematol. 79(suppl. 1):1991;56-59.
147. Peracchia A., Ruol A., De Besi P. Malignancies of the oesophagus. Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. 1995;1095-1116 Oxford University Press, Oxford.
148. Peters G.J., Ackland S.P. New antimetabolites in preclinical and clinical development. Exp Opin Invest Drugs. 5:1996;637-679.
149. Peters G.J., Jansen G. Resistance to antimetabolites. Schilsky R.L., Milano G.A., Ratain M.J. Principles of Antineoplastic Drug Development and Pharmacology. 1996;543-585 Marcel Dekker, New York.
150. Peters G.J., Köhne C.H. Fluoropyrimidines as antifolate drugs. Jackman A.L. Antifolate Drugs in Cancer Therapy. 1999;101-145 Humana Press Inc, Totowa.
151. Peters G.J., Van Groeningen C.J. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol. 2:1991;469-480.
152. Peters G.J., Van Dijk J., Laurensse E., Van Groeningen C.J., Lankelma J., Leyva A., Nadal J., Pinedo H.M. In vitro biochemical and in vivo biological studies of uridine "rescue" of 5-fluorouracil. Br J Cancer. 57:1988;259-265.
153. Peters G.J., Schornagel J., Milano G.A. Clinical pharmacokinetics of antimetabolites. Cancer Surv. 17:1993;123-156.
154. Peters G.J., Van der Wilt C.L., Van Groeningen C.J. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer. 30A:1994;1408-1411.
155. Peters G.J., Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Braakhuis B.J.M. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 22(suppl. 11):1995;72-79.
156. Petrelli N., Douglas H.O. Jr., Herrera L., Russell D., Stablein D.M., Bruckner H.W., Mayer R.J., Schinella R., Green M.D., Muggia F.M., Megibow A., Greenwald E.S., Bukowski R.M., Harris J.H., Levin B., Gaynor E., Loutfi A., Kalser M.H., Barkin J.S., Benedetta P., Woolley P.V., Nauta R., Weaver D.W., Leichman L.P. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma. a prospective randomized phase III trial J Clin Oncol. 7:1989;1419-1426.
157. Piedbois P., Buyse M., Rustum Y., Machover D., Erlichman C., Carlson R.W., Valone F., Labianca R., Doroshow J.H., Petrelli N. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. evidence in terms of response rate J Clin Oncol. 10:1992;896-903.
158. Pinkel D. Intravenous mercaptopurine. life begins at 40 J Clin Oncol. 11:1993;1826-1831.
159. Plunkett W., Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 20:1993;50-63.
160. Plunkett W., Gandhi V. Pharmacology of purine nucleoside analogues. Hematol Cell Ther. 38(suppl. 2):1996;S67-S74.
161. Plunkett W., Huang P., Xu Y.X., Heinemann V., Grunewald R., Gandi V. Gemcitabine. metabolism, mechanisms of action, and self-potentiation Semin Oncol. 22(suppl. 11):1995;3-11.
162. Poon M.A., O'Connell M.J., Wieand H.S., Krook J.E., Gerstner J.B., Tschetter L.K., Levitt R., Kardinal C.G., Mailliard J.A. Biochemical modulation of fluorouracil with leucovorin. confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer J Clin Oncol. 9:1991;1967-1972.
163. Porter D.J.T., Chestnut W.G., Merrill B.M., Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem. 267:1992;5236-5242.
164. Powell B.L., Wang L.-M., Gregory B.W., Case L.D., Kucera G.L. GM-CSF and asparaginase potentiate ara-C cytotoxicity in HL-60 cells. Leukemia. 9:1995;405-409.
165. Pritchard D.M., Watson A.J.M., Potten C.S., Jackman A.L., Hickman J.A. Inhibition of uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil. evidence for the involvement of RNA perturbation Proc Natl Acad Sci USA. 94:1997;1795-1799.
166. Pui C.H., Evans W.E. Acute lymphoblastic leukemia in infants. J Clin Oncol. 17:1999;438-440.
167. Radparvar S., Houghton P.J., Houghton J.A. Characteristics of thymidylate synthase purified from a human colon adenocarcinoma. Arch Biochem Biophys. 260:1988;342-350.
168. Rassman I., Thödtmann R., Depenbrock H., Blatter J., Gatzemeier U., Tasstetter J., Hanauske A.-R. Gemcitabine and etoposide in small cell lung cancer. phase I and II trials Semin Oncol. 24(suppl. 7):1997;75-85.
169. Raymond E., Buquetfagot C., Djelloul S., Mester J., Cvitkovic E., Allain P., Louvet C., Gespach C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs. 8:1997;876-885.
170. Reuter C., Auf der Landwehr U., Schleyer E., Zühlsdorf M., Ameling C., Rolf C., Wörnmann B., Büchner T., Hiddemann W. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia. 8:1994;217-225.
171. Rinaldi M., Crinò L., Scagliotti G., Mosconi A.M., De Marinis F., Gridelli C., Selvaggi G., Darwish S., Bartolucci R., Calandri C., Sassi M., Tonato M. A new schedule of gemcitabine-cisplatin in advanced non small cell lung cancer (NSCLC) with two different cisplatin dose levels. a phase II randomized trial Proc Am Soc Clin Oncol. 17:1998;470a.
172. Romanini A., Li W.W., Colofiore J.R., Bertino J.R. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. J Natl Cancer Inst. 84:1992;1033-1038.
173. Ruiz van Haperen V.W.T., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol. 46:1993;762-766.
174. Ruiz van Haperen V.W.T., Veerman G., Boven E., Noordhuis P., Vermorken J.B., Peters G.J. Schedule-dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol. 48:1994;1327-1339. a.
175. Ruiz van Haperen V.W.T., Veerman G., Eriksson S., Boven E., Stegmann A.P.A., Hermsen M., Vermorken J.B., Pinedo H.M., Peters G.J. Development and characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Res. 54:1994;4138-4143. b.
176. Rustum Y.M., Raaymakers R.A.P. 1-β-Arabinofuranosylcytosine in therapy of leukemia - preclinical and clinical overview. Pharmacol Ther. 56:1992;307-321.
177. Saltz L.B., Locker P.K., Pirotta N., Elfring L.L., Miller L.L. Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily ×5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol. 18:1999;233a.
178. Sandler A., Nemunaitis J., Dehnam C., Cormier Y., Von Pawel J., Niyikiza C., Bguyen B., Einhorn L. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 17:1998;454a.
179. Santini V., Dippolito G., Bernabei P.A., Zoccolante A., Ermini A., RossiFerrini P. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60. direct comparison of cytotoxicity and cellular Ara-C uptake enhancement Leuk Res. 20:1996;37-45.
180. Santoro A., Santoro M., Maiorino L., Forestieri V., Forestieri P. Phase II trial of gemcitabine plus carboplatin for urothelial transitional cell carcinoma (UTCC) in advanced or metastatic stage. Ann Oncol. 9(suppl. 2):1998;169.
181. Schmiegelow K., Schroder H., Gustafsson G., Kristinsson J., Glomstein A., Salmi T., Wranne L., for the Nordic Society for Pediatric Hematology and Oncology Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol. 13:1995;345-351.
182. Schwartz G.K., Kemeny N., Bertino J., Saltz L., Sugarman A., Kelsen D.K., Tong W., Lowery C. Interim results of phase I trial suggests that "Tomudex" (raltitrexed) may act synergistically with (5-fluorouracil) 5-FU in patients with advanced colorectal cancer. Ann Oncol. 9(suppl. 2):1998;159.
183. Seiter K., Kemeny N., Martin D., Schneider A., Williams L., Colofiore J., Sawyer R. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. Cancer. 71:1993;1875-1881.
184. Shewach D.S., Hahn T.M., Chang E., Hertel L.W., Lawrence T.S. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223.
185. Sinnige H.A.M., Buter J., Devries E.G.E., Uges D.R.A., Roenhorst H.W., Verschueren R.C.J., Sleijfer D.T., Willemse P.H.B., Mulder N.H. Phase I-II study of the addition of alpha-2A interferon to 5-fluorouracil leucovorin - pharmacokinetic interaction of alpha-2A interferon and leucovorin. Eur J Cancer. 29A:1993;1715-1720.
186. Smid K., Van der Wilt C.L., Peters G.J. Effects of novel antifolates on the binding of 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP) to bacterial and human thymidylate syntase (TS). Ann Oncol. 7(suppl. 1):1996;90.
187. Smith M.A., Singer C.R.J., Pallister C.J., Smith J.G. The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro. Br J Haematol. 90:1995;767-773.
188. Smitskamp-Wilms E., Pinedo H.M., Veerman G., Ruiz van Haperen V.W.T., Peters G.J. Postconfluent multilayered cell line cultures for selective screening of gemcitabine. Eur J Cancer. 34:1998;921-926.
189. Spears C.P., Shahinian A.H., Moran R.G., Heidelberg C., Corbett T.H. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res. 42:1982;450-456.
190. Spector T., Harrington J.A., Porter D.J.T. 5-Ethynyluracil (5-ethynyluracil). inactivation of dihydropyrimidine dehydrogenase in vivo Biochem Pharmacol. 46:1993;2243-2248.
191. Spector T., Porter D.J.T., Nelson D.J. 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future. 19:1994;565-571.
192. Steele G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy. the concept of additivity Int J Radiat Oncol Biol Phys. 5:1979;85-91.
193. Taguchi T., Nakano Y., Fujii S., Shirasaka T. Determination of 5-fluorouracil levels in tumors, blood, and other tissues. Jpn J Cancer Chemother. 5:1978;1167-1172.
194. Takechi T., Nakano K., Uchida J., Mita A., Toko K., Takeda S., Unemi N., Shirasaka T. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafor, in experimental tumor models in rats. Cancer Chemother Pharmacol. 39:1997;205-211.
195. Tatsumi K., Fukushima M., Shirasaka T., Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 78:1987;748-755.
196. Teicher B.A., Gunner L.J., Roach J.A. Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes. Br J Cancer. 52:1985;833-839.
197. Tobias J.S. Current role of chemotherapy in head and neck cancer. Drugs. 43:1992;333-345.
198. Tolis C., Peters G.J., Ferreira C.G., Pinedo H.M., Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer. 35:1999;796-807.
199. Tsai C.M., Chang K.T., Chen J.Y., Chen Y.M., Chen M.H., Perng R.P. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu1. Cancer Res. 56:1995;794-801.
200. Unemi N., Takeda S., Tajima K. Studies on combination therapy with 1-(tetrahydro-2 furanyl)-5-fluorouracil plus uracil. I. Effect of coadministration of uracil on the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and the level of 5-fluorouracil in AH 130 bearing rats. Chemotherapy. 29:1981;164-175.
201. Van der Wilt C.L., Peters G.J. New targets for pyrimidine antimetabolites for the treatment of solid tumors. Part 1. Thymidylate synthase. Pharm World Sci. 16:1994;84-103.
202. Van der Wilt C.L., Pinedo H.M., Smid K., Peters G.J. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res. 52:1992;4922-4928. a.
203. Van der Wilt C.L., Van Laar J.A.M., Gyergyay F., Smid K., Peters G.J. Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer. 28A:1992;2017-2024. b.
204. Van der Wilt C.L., Pinedo H.M., De Jong M., Peters G.J. Effect of folate diastereoisomers on the binding of 5-fluoro-2′-deoxyuridine-5′-monophosphate to thymidylate synthase. Biochem Pharmacol. 45:1993;1177-1179.
205. Van der Wilt C.L., Braakhuis B.J.M., Pinedo H.M., De Jong M., Smid K., Peters G.J. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate. potentiating or reversing effect? Int J Cancer. 61:1995;672-678. a.
206. Van der Wilt C.L., Pinedo H.M., Kuiper C.M., Smid K., Peters G.J. Biochemical basis for the combined antiproliferative effect of AG337 or ZD1694 and 5-fluorouracil. Proc Am Assoc Cancer Res. 36:1995;379. b.
207. Van der Wilt C.L., Smid K., Noordhuis P., Aherne G.W., Peters G.J. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer. 33:1997;471-478.
208. Van der Wilt C.L., Kuiper C.M., Peters G.J. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines. Oncol Res. 11:1999;383-391.
209. Van Groeningen C.J., Peters G.J., Leyva A., Laurensse E.J., Pinedo H.M. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. J Natl Cancer Inst. 81:1989;157-162.
210. Van Groeningen C.J., Peters G.J., Pinedo H.M. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. Ann Oncol. 4:1993;317-320.
211. Van Hoefer U., Harstrick A., Köhne C.H., Achterrath W., Rustum Y.M., Seeber S., Wilke H. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol. 17:1999;907-913.
212. Van Laar J.A.M., Van der Wilt C.L., Smid K., Noordhuis P., Rustum Y.M., Pinedo H.M., Peters G.J. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-b carcinoma tumor model. Clin Cancer Res. 2:1996;1327-1333.
213. Van Moorsel C.J.A., Peters G.J., Pinedo H.M. Gemcitabine. future prospects of single-agent and combination studies Oncologist. 2:1997;127-134. a.
214. Van Moorsel C.J.A., Veerman G., Bergman A.M., Guechev A., Vermorken J.B., Postmus P.E., Peters G.J. Combination chemotherapy studies with gemcitabine. Semin Oncol. 24(suppl. 7):1997;17-23. b.
215. Van Moorsel C.J.A., Kroep J.R., Pinedo H.M., Veerman G., Voorn D.A., Postmus P.E., Vermorken J.B., Van Groeningen C.J., Van der Vijgh W.J.F., Peters G.J. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol. 10:1999;441-448. a.
216. Van Moorsel C.J.A., Pinedo H.M., Veerman G., Bergman A.M., Kuiper C.M., Vermorken J.B., Van der Vijgh W.J.F., Peters G.J. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br J Cancer. 35:1999;808-814. b.
217. Van Moorsel C.J.A., Pinedo H.M., Veerman G., Guechev A., Smid K., Loves W.J.P., Vermorken J.B., Postmus P.E., Peters G.J. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol. 57:1999;407-415. c.
218. Van Moorsel C.J.A., Pinedo H.M., Veerman G., Vermorken J.B., Postmus P.E., Peters G.J. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer. 35:1999;808-814. d.
219. Van Moorsel C.J.A., Bergman A.M., Veerman G., Voorn D.A., Ruiz van Haperen V.W.T., Kroep J.R., Pinedo H.M., Peters G.J. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukemia cell lines. Biochim Biophys Acta. 1474:2000;5-12.
220. Van Triest B., Peters G.J. Thymidylate synthase. a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer Oncology. 57:1999;179-194.
221. Vermorken J.B., Claessen A.M.E., van Tinteren H., Gall H.E., Ezinga R., Meijer S., Scheper R.J., Meijer C.J.L.M., Bloemena E., Ransom J.H., Hanna M.G. Jr., Pinedo H.M. Active specific immunotherapy for stage II and stage III human colon cancer. a randomised trial Lancet. 353:1999;345-350.
222. Veronesi U., Goldhirsch A., Yarnold J. Breast cancer. Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. 1995;1243-1289 Oxford University Press, Oxford.
223. Vokes E.E., Gregor A., Turrisi A.T. Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol. 25(suppl. 9):1998;66-69.
224. Von der Maasse H., Andersen L., Crino L., Weissbach L., Dogliotti L. A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc Am Soc Clin Oncol. 16:1997;324a.
225. Wadler S., Lembersky B., Atkins M., Kirkwood J., Petrelli N. Phase II trial of fluorouracil and recombinant interferon α-2a in patients with advanced colorectal carcinoma. an Eastern Cooperative Oncology Group Study J Clin Oncol. 9:1991;1806-1810.
226. Webb J.L. Effect of more than one inhibitor. Enzymes and Metabolic Inhibitors. 1963;66-79 Academic Press, New York.
227. Weichsel A., Montfort W.R. Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89. Nature Struct Biol. 2:1995;1095-1101.
228. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M., Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes. correlates of molecular structure and biological activity Mol Pharmacol. 48:1995;659-671.
229. Zittoun R. Chemotherapy of acute myelogenous leukemia. A review. Leukemia. 6:1992;36-38.